ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

END TREATMENT RESPONSE OF CHRONIC HEPATITIS C VIRUS GENOTYPE 3 INFECTION WITH SOFOSBUVIR AND RIBAVIRIN AT 24 WEEKS

Dr. Taj Mohammad Khan, Dr. Muhammad Bilal, Dr. Salman Khan, Dr. Muhammad Tariq Mehr, Nisar Khan, Dr. Atta Ullah Khan.

Background: Chronic hepatitis C is a global problem and is particularly concentrated in the developing world. There is paucity of literature regarding management of chronic hepatitis C in lower- & middle-income countries. Objectives: The aim of this study was to present management strategies in chronic hepatitis C virus infections using the novel chemotherapeutic drugs. Methods: This is a prospective cohort study of six months duration which was conducted at the department of internal medicine, Mufti Mehmood Teaching Hospital, Dear Ismail Khan. We included adult (14-75 Years) hepatitis C positive naive patients detected on PCR from both genders. Follow up PCR was performed at 12 weeks and 24 weeks. Excluded cases were recurrenthepatotis C infection, cirrhotic, Hepatocellular Carcinoma, hypersensitivity to the chemotherapeutics and those with multiple hepatic viral infections. Data was collected about patient demographics, inclusion PCR results, treatment details, and follow-up PCR readings. Results: A total of 115 patients were included in this study. There were 60 (52.2%) males and 55 (47.8%) females. The age range was 14 to 75 years with a mean age of 40.02 ± 13.09 years. Among the 111 patient’s data which was available for analysis, 106 (92.2%) patients PCR was negative for viral RNA, while it was positive for 5 (4.3%) cases. Conclusion: Sofosbuvir and Ribavirin combination is very effective in treatment naive chronic hepatitis C patients with Genotype 3 in Pakistani population with minimal side effects and is cost effective. Key Words:Sofosbuvir, Ribavirin, HCV infection, ETR (End Treatment Response).

FULL TEXT